北京若生智能科技有限公司
Drug Database
HY

hyaluronic acid (Provisc)

✓ Approved

Novartis AG · 治疗药物

什么是 hyaluronic acid？

hyaluronic acid 是一种治疗药物，由Novartis AG研发。该药已获批，用于治疗相关适应症。

药物档案

商品名Provisc
公司Novartis AG
状态Approved
来源： ClinicalTrials.gov, Novartis AG

治疗适应症

hyaluronic acid 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAdjuvant therapy✓ Approved
Eye disordersDry eyePreclinical

相关研究文献

PubMedMolecular nutrition & food research2026-09-10

Black Rice Anthocyanin-Hyaluronic Acid Complex Alleviates Hyperuricemia-Associated Renal Injury Through Synergistic Inhibition of the TLR4/NF-κB Pathway and Modulation of Uric Acid Transport.

Zhao Jingyun J, Liu Ya Y, Huang Yuanjing Y, Xu Gang G et al.

Hyperuricemia-associated renal injury is closely linked to oxidative stress and inflammation, highlighting the need for safe dietary intervention. This study evaluated the protective effects of a black rice anthocyanin (ATC)-hyaluronic acid complex (HAA) against uric acid (UA)-induced injury. In UA-induced human renal proximal tubular epithelial (HK-2) cells, black rice ATCs, HA, and HAA improved cell viability and antioxidant defenses, as shown by increased glutathione (GSH) levels and catalase (CAT) and superoxide dismutase (SOD) activities. They also reduced malondialdehyde (MDA), reactive oxygen species (ROS), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β). HAA produced a greater reduction in TLR4/NF-κB-related inflammatory gene expression, suggesting that its cytoprotective and anti-inflammatory effects may be associated with modulation of this inflammatory axis. In hyperuricemic mice, HAA lowered serum UA, creatinine, and blood urea nitrogen levels, inhibited hepatic xanthine oxidase and adenosine deaminase activities, and attenuated renal histopathological injury. HAA also reduced the mRNA expression of urate reabsorption-related genes, including GLUT9, OAT4, and OAT10, while increasing that of urate excretion-related genes, including OAT1 and ABCG2, which may contribute to improved urate homeostasis. These findings support the potential of HAA as a functional dietary ingredient for the management of hyperuricemia-associated metabolic disturbances and renal injury.

PMID 42717777
阅读全文 →
PubMedKorean journal of ophthalmology : KJO2026-09-10

Comparing the Efficacy and Tolerability of Two 0.3% Hyaluronic Acid Eye Drop Preparations for Dry Eye Disease: a Randomized Trial.

Lee Jee Hye JH, Kwon Min-Jung MJ, Jeon Youngseo Y, Yoon Hye Yeon HY et al.

To evaluate the efficacy and tolerability of a new 0.3% non-preservative low viscosity hyaluronic acid (HA) preparation (Kynex 3), compared to the same concentration of HA (Hyalein Mini 0.3%) for the treatment of dry eye disease. A prospective, single-center, randomized, double-blinded trial (group 1; Kynex 3 vs group 2; Hyalein Mini 0.3%) was performed over 8 weeks. Patients with dry eye symptoms and ocular surface staining score ≥ 2 by the Oxford system, and tear break-up time (TBUT) < 10 s were included. Efficacy outcomes included improvements in TBUT, Schirmer I value, corneal and conjunctival staining scores, and ocular surface disease index (OSDI) at 4 and 8 weeks. Tolerability was assessed using instillation discomfort scores on day 0 and at 4 and 8 weeks. Twenty-three patients were analyzed. Both 0.3% HA preparations significantly improved the TBUT and OSDI scores at 4 and 8 weeks compared with those on day 0. Reduction in the corneal staining score and instillation discomfort scores were significant in group 1 at week 4, and both groups showed a similar statistically significant reduction at week 8. Conjunctival staining and Schirmer I scores did not improve in either group. Both 0.3% HA eye drops effectively improved dry eye symptoms and TBUT. Regarding corneal staining and instillation discomfort scores, significant within-group reduction was shown in one group (Kynex 3) at week 4, without a significant between-group difference.

PMID 42717754
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-09-10

Co-Delivery of Sustained Release Chondroitinase ABC-37 With Human iPSC-Derived Neural Progenitors Promotes Transplant Survival and Functional Recovery in a Rodent Model of Stroke.

Letko Khait Nitzan N, Li David Xinzheyang DX, Guo Keyi K, Cui Hong H et al.

Stroke is a leading cause of disability worldwide, yet effective treatments to regenerate damaged tissue remain elusive. We investigated tissue regeneration and functional recovery post-stroke in an animal model with a combinatorial approach leveraging human induced pluripotent stem cell-derived neural progenitor cells (NPCs) and a sustained-release formulation of a re-designed, thermostable chondroitinase ABC (ChASE37). We optimized an in situ gelling, injectable hyaluronic acid (HA)-based hydrogel with the incorporation of laminin to deliver NPCs to the cavity in a rat model of sub-acute ischemic stroke. We delivered ChASE37 by affinity release from a methylcellulose hydrogel (ChASE37-AR) to the stroke-injured brain by epicortical injection. ChASE37-AR retained long-term enzymatic activity, as demonstrated by degradation of inhibitory chondroitin sulfate proteoglycans (CSPGs) in the injured tissue, with no evidence of immunogenicity. Each treatment - ChASE37-AR, NPCs, and their co-delivery - significantly improved motor function as early as 3 weeks after a single administration. Critically, only the combined therapy supported long-term survival and neuronal differentiation of transplanted cells, suggesting that ChASE37-AR has a role beyond CSPG degradation. This strategy presents a modular, clinically relevant platform for tissue regeneration post-stroke. Together, these findings suggest that the co-delivery of NPCs and sustained-release ChASE37 may be promising for stroke treatment.

PMID 42717514
阅读全文 →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-09-10

Intraoperative Quantification of Incision-Site Descemet Membrane Detachment During Phacoemulsification: A Paired-Eye Comparison of Longitudinal and Torsional Ultrasound.

Bulir Petr P, Studeny Pavel P

To quantify the extent of clinically non-significant Descemet membrane detachment (DMD) at the clear corneal incision (CCI) during phacoemulsification and to compare its extent between longitudinal and torsional ultrasound modulation as a morphological marker of local tissue-instrument interaction. In this prospective contralateral-eye comparative randomized study, 14 patients (28 eyes) undergoing bilateral cataract surgery were included. One eye received longitudinal and the fellow eye torsional ultrasound (Constellation system, Alcon). DMD was assessed intraoperatively using microscope video recordings under red reflex illumination. Still images were analyzed, and DMD area (mm2) at the internal wound was measured. Correlations with cumulative dissipated energy (CDE) was evaluated. Incision-site DMD was detected in all analyzed cases (100%) using intraoperative red reflex-based visualization. Mean DMD area was 1.33 ± 0.43 mm2 (longitudinal) and 2.37 ± 0.67 mm2 (torsional), with a mean difference of 1.04 mm2 ± 0.74 mm2 (95% CI, 0.60-1.48). The paired analysis demonstrated a highly significant difference (p < 0.001). No correlation was found between DMD extent and CDE. Clinically non-significant incision-site DMD appears to be a frequent intraoperative morphological phenomenon during phacoemulsification when assessed using sensitive visualization techniques. Torsional ultrasound was associated with a significantly greater DMD extent than longitudinal modulation. Rather than indicating greater clinical damage, DMD area may serve as a sensitive quantitative morphological marker of local tissue-instrument interaction at the corneal incision. Its potential value therefore lies primarily in the comparative evaluation and future refinement of phacoemulsification technologies, while the clinical significance of these subtle morphological differences remains to be established.

PMID 42719804
阅读全文 →
PubMedGeobiology2026-09-10

Origins of Improved Hardness in Bioinspired Aragonite Precipitated Under Simulated Biologic Conditions.

Chomhom Boontharee B, Farfan Gabriela A GA, Greeves Samantha S, Penkman Kirsty K et al.

Biogenic aragonite is a composite of mineral and biomolecules that exhibits superior material properties compared to its inorganic analog. This superiority underpins the success of the bioaragonite structures which support coral reefs and shell fisheries, yet the mechanisms improving the physical resilience of bioaragonite are not well understood. In this study, aragonite is synthesised under chemical conditions which simulate those of calcification sites in marine organisms. Aspartic acid, glutamic acid, and glycine in solution are incorporated into the aragonite at concentrations typically observed in marine biominerals and are observed to significantly improve aragonite Vickers hardness. Aspartic acid is incorporated more efficiently than glutamic acid or glycine, but for comparable amounts of amino acid incorporation, glycine improves aragonite hardness significantly more than either aspartic or glutamic acid. Glycine and glutamic acid incorporation reduce the aragonite grain size, thereby improving resilience to indentation via energy dissipation along grain boundaries. In contrast, aspartic acid also improves hardness on a smaller scale, possibly due to crystal structure distortions. These results suggest that amino acid incorporation influences biogenic aragonite hardness via multiple mechanisms and provide a prototype for exploring the influence of more complicated biomineral proteins.

PMID 42720183
阅读全文 →
PubMedThe AAPS journal2026-09-10

Verification of a Physiologically-based Pharmacokinetic Model for Predicting CYP3A4-mediated Simvastatin and Simvastatin Acid Drug-drug Interactions.

Morse Bridget L BL, Han Bing B, Alberts Jeffrey J JJ, Posada Maria M MM et al.

Simvastatin is a commonly prescribed medication and a sensitive CYP3A4 substrate requiring dosage modification with CYP3A4 precipitants. Unlike other CYP3A4 substrates, grapefruit juice (GFJ) causes the largest increase in simvastatin exposure of any CYP3A4 inhibitor, leading to misunderstanding of simvastatin fraction escaping CYP3A4 metabolism in the gut (Fg, CYP3A4) and fraction metabolized by CYP3A4 in the liver (fm,CYP3A4). Simvastatin is a prodrug that is converted to the active simvastatin acid, though the mechanisms responsible for in vivo simvastatin acid formation are not well-understood. GFJ also decreases the simvastatin acid:simvastatin exposure ratio, suggesting inhibition of simvastatin acid formation. In the current work, we used a static approach to define simvastatin CYP3A4 parameters, using clinical data with index substrate midazolam; estimated simvastatin Fg,CYP3A4 and fm,CYP3A4 were ~ 0.4 and ~ 0.9, respectively. In vitro data assessing the stability of simvastatin and simvastatin acid demonstrated rapid conversion in gastric fluid that was highly pH-dependent. A simvastatin PBPK model was constructed incorporating these CYP3A4 parameters and simvastatin acid formation in stomach, intestine and plasma. The model reproduced the nonlinear pharmacokinetics of simvastatin and CYP3A4 precipitant effects, thus qualifying the model for prediction of CYP3A4-mediated interactions on both simvastatin and simvastatin acid. Simvastatin overall Fg was estimated as ~ 0.2, lower than the Fg,CYP3A4 due to additional intestinal esterase-mediated formation of simvastatin acid. The simvastatin-GFJ effect was explained by inhibition of this intestinal simvastatin acid formation, along with CYP3A4 inhibition. The unique effect of food on the simvastatin acid:simvastatin exposure ratio could also be replicated using this PBPK model.

PMID 42717157
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hyaluronic acid